Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02515305 · ClinicalTrials.gov registry record · Phase 3
Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris
A Phase 3 study, sponsored by Padagis.
- Completed
- Registry status
- Phase 3
- Development phase
- 890
- Enrollment target
NCT02515305: Completed Phase 3 study, sponsored by Padagis.
NCT02515305 is a Phase 3 study that has completed, run by Padagis. The registered enrollment target is 890 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02515305, a Phase 3 study, has completed, sponsored by Padagis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 890 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment acne vulgaris
Interventions
- DRUG Clindamycin and Benzoyl Peroxide Gel (combination)
- DRUG Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)
- DRUG Placebo gel (combination)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 890 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-06 |
| Phase | Phase 3 |
What the finished NCT02515305 record still lists
NCT02515305 is an interventional study that assigns participants to a tested intervention. The registered 890 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% higher).
The record links to 0 conditions, and to 3 interventions - of which Clindamycin and Benzoyl Peroxide Gel (combination) is the first listed.
NCT02515305 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02515305 about?
NCT02515305 is a clinical study titled "Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris". The purpose of this study is to compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment acne vulgaris
What is the current status of trial NCT02515305?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 890 participants. The study started on 2015-07. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02515305?
The interventions under investigation include: Clindamycin and Benzoyl Peroxide Gel (combination) (DRUG), Clindamycin and Benzoyl Peroxide Gel (Reference) (combination) (DRUG), Placebo gel (combination) (DRUG).
Who is sponsoring clinical trial NCT02515305?
This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02515305's enrollment target sits among peer trials
890 364th of 2000 higher than 1,637 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03564340 · 890 participants · Phase 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT05855200 · 892 participants · Phase 3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- NCT04862663 · 895 participants · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- NCT07196748 · 882 participants · Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia